Catalent Receives P&G External Business Partner of the Year Award

Catalent Receives P&G External Business Partner of the Year Award

SOMERSET, N.J. – February 18, 2019— Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has received The Procter & Gamble Company’s (P&G) highest external business partner recognition, the External Business Partner of the Year Award.

The award recognizes the performance of Catalent’s two state-of-the-art softgel manufacturing facilities in Ontario, Canada which have been supplying P&G Personal Healthcare brands in the U.S. and Canada. Catalent also launched additional cough and cold OTC product line extensions with P&G in 2018, which are supplied from Catalent’s facilities in Ontario.

“Catalent has been P&G’s preferred softgel supplier for twenty years,” commented Dr. Aris Gennadios, President, Catalent Softgel Technologies. He added, “We continue to collaborate closely with P&G Personal Healthcare to bring innovative products to consumers.”

“I congratulate and thank all of our award winners. They are critical partners in accomplishing our purpose,” said Stew Atkinson, Chief Purchasing Officer, P&G. “P&G’s supplier eco-systems are creating value for consumers, customers, P&G and our suppliers. I am proud of what we have accomplished, and we will continue to raise the bar on superiority, productivity and citizenship together.”

Catalent’s Ontario facilities in Strathroy and Windsor offer softgel development and manufacturing capabilities for both the pharmaceutical and consumer health industries. The two sites combine integrated formulation, manufacturing, analytical and packaging services to provide full service turnkey solutions to partners.

For more information, please see Procter & Gamble’s press release: https://news.pg.com/press-release/pg-corporate-announcements/pg-recognizes-top-suppliers-powering-global-supply-network-

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Northern Exposure Public Relations Limited
Tel: +44 161 728 5880
Mob: +44 7967 339273
Follow us on twitter @NrthnExposurePR

Share

twitterlinkedinmail

About the Author and BIOCOM CRO Board Member